

AMENDMENTS TO THE CLAIMS

Please cancel claims 18-20 and amend claim 1 as follows:

1. (currently amended) A process for *in vivo* expression of longer than seven days of a non-viral, linear DNA nucleic acid sequence from a delivered expression cassette, comprising:
 - a) providing the expression cassette comprising the nucleic acid sequence operably linked to a promoter;
 - b) forming a non-viral, linearized plasmid DNA vector comprising the expression cassette; and,
 - c) delivering the non-viral, linearized plasmid DNA vector to a hepatocyte in a mammal, wherein providing the expression cassette on the non-viral, linearized plasmid DNA vector results in increased expression in the hepatocyte after seven days defined by at least 20% more gene product than is expressed from a supercoiled plasmid from which the linearized plasmid is derived of longer than seven days of the nucleic acid sequence.
2. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains blunt ends.
3. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains sticky ends.
4. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains a blunt end and a sticky end.
5. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is generated by restriction enzyme digestion.
6. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is generated by polymerase chain reaction.
7. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette isolated from a plasmid backbone.

8. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette which is flanked by sequence derived from inner Tn5 transposase recognition elements.
9. (previously presented) The process of claim 8, wherein the non-viral, linear DNA vector ends are blunt.
10. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette which is flanked by sequence derived from inner outer Tn5 transposase recognition elements.
11. (previously presented) The process of claim 10, wherein the non-viral, linear DNA vector ends are blunt.
12. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector contains an expression cassette which is flanked by chimeric ends derived from Tn5 transposase recognition elements.
13. (previously presented) The process of claim 12, wherein the non-viral, linear DNA vector ends are blunt.
14. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is delivered to cells intravascularly.
15. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector are delivered intravascularly using pressure.
16. (canceled)
17. (previously presented) The process of claim 1, wherein the non-viral, linear DNA vector is delivered by direct interstitial injection.
18. (canceled)
19. (canceled)
20. (canceled)